Danel (DANE) AI Stock Analysis

• Market Cap: 2.87B
• Dividend Yield: 2.98%
• Average Volume (3M): 11.82K
• Price to Earnings (P/E): 150.5
• Beta (1Y): 0.94
• Revenue Growth: 5.94%
• EPS Growth: -52.48%
• Country: IL
• Employees: 4,290
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Medical - Care Facilities
• EPS (TTM): 587.00
• Shares Outstanding: 5,918,127
• 10 Day Avg. Volume: 13,517
• 30 Day Avg. Volume: 11,824
• PEG Ratio: -0.40
• Price to Book (P/B): 5.14
• Price to Sales (P/S): 0.84
• P/FCF Ratio: 12.39
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: 48,287.00 ▲(4.00% Upside)

Danel's overall stock score is primarily impacted by its financial performance challenges, including declining margins and cash flow issues. The high P/E ratio suggests overvaluation, further weighing on the score. Technical indicators show mixed signals, with bearish momentum offset by neutral RSI levels.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong demand for Danel's software solutions, supporting long-term business expansion and market penetration.

Subscription-Based Model

The subscription-based model provides predictable and recurring revenue streams, enhancing financial stability and customer retention.

Partnerships

Strategic partnerships expand market reach and integration opportunities, strengthening Danel's competitive position in the healthcare and financial sectors.

Negative Factors

Declining Margins

Declining margins suggest challenges in cost management and pricing power, potentially impacting long-term profitability and competitive edge.

Cash Flow Issues

Reduced free cash flow growth limits Danel's ability to invest in growth opportunities and may constrain financial flexibility over time.

Decreased Return on Equity

A significant decrease in return on equity indicates reduced profitability and efficiency in using shareholders' equity, affecting investor confidence.

Danel Business Overview & Revenue Model

Company Description

Danel (DANE) is a technology-driven company specializing in the development and deployment of innovative software solutions for the healthcare and financial sectors. The company focuses on enhancing operational efficiencies and customer engagement through its suite of applications, which includes data analytics tools, patient management systems, and secure transaction platforms. Danel aims to leverage cutting-edge technologies to empower organizations in managing their processes more effectively and improving service delivery.

How the Company Makes Money

Danel generates revenue primarily through a subscription-based model, where clients pay for access to its software solutions on a monthly or annual basis. In addition to subscription fees, the company also earns income from consulting services, which include implementation, customization, and ongoing support for its clients. Key partnerships with healthcare providers and financial institutions further bolster Danel's revenue streams, allowing for integration of its products into existing systems and expanding its market reach. Moreover, Danel may receive additional income from licensing its technology to third parties, thereby creating multiple pathways for revenue generation.

Danel Financial Statement Overview

Summary

Danel exhibits strong revenue growth and stable financial health, but faces challenges in profitability and operational efficiency. The company maintains a solid balance sheet with moderate leverage and a strong cash flow position, which supports its growth trajectory. However, improving margins and returns on equity could enhance shareholder value.

Income Statement

Danel's income statement shows moderate growth and profitability. The TTM revenue growth rate is strong at 91.7%, indicating robust expansion. However, margins are relatively low, with a gross profit margin of 18.34% and a net profit margin of 0.83%, suggesting limited profitability. The EBIT and EBITDA margins have decreased over time, reflecting potential operational inefficiencies.

Balance Sheet

The balance sheet is stable with a manageable debt-to-equity ratio of 0.69 in the TTM period, indicating moderate leverage. The return on equity is low at 4.71%, suggesting limited returns for shareholders. The equity ratio stands at 36.89%, reflecting a solid equity base relative to total assets.

Cash Flow

Cash flow analysis reveals strong free cash flow growth of 273.4% in the TTM period, highlighting improved cash generation. The operating cash flow to net income ratio is 4.59, indicating healthy cash flow relative to earnings. However, the free cash flow to net income ratio has decreased slightly, suggesting potential challenges in converting earnings to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.87B	2.77B	2.51B	2.36B	2.29B	1.98B
Gross Profit	516.65M	510.71M	458.31M	464.44M	492.51M	410.04M
EBITDA	166.95M	223.61M	84.01M	206.17M	283.44M	216.13M
Net Income	21.54M	20.51M	-11.22M	115.79M	174.15M	127.36M
Balance Sheet
Total Assets	1.36B	1.31B	1.30B	1.27B	1.13B	1.02B
Cash, Cash Equivalents and Short-Term Investments	202.20M	251.20M	185.15M	139.98M	81.09M	141.41M
Total Debt	342.80M	363.56M	376.07M	335.48M	262.58M	193.71M
Total Liabilities	838.21M	853.41M	816.38M	758.19M	729.68M	688.47M
Stockholders Equity	518.71M	452.26M	471.44M	493.17M	364.45M	291.45M
Cash Flow
Free Cash Flow	166.64M	187.65M	156.91M	141.66M	180.19M	243.20M
Operating Cash Flow	244.54M	223.06M	206.72M	205.71M	231.64M	266.34M
Investing Cash Flow	-77.80M	-34.05M	-73.82M	-79.02M	-124.25M	-56.24M
Financing Cash Flow	-146.16M	-122.96M	-87.73M	-67.80M	-167.71M	-133.40M

Danel Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 46430.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:DANE, the sentiment is Positive. The current price of 46430 is below the 20-day moving average (MA) of 47842.00, below the 50-day MA of 46729.96, and above the 200-day MA of 44443.89, indicating a bullish trend. The MACD of 804.64 indicates Negative momentum. The RSI at 58.17 is Neutral, neither overbought nor oversold. The STOCH value of 87.13 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:DANE.

Danel Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WLFD	74 Outperform	770.99M	22.78	―	―	―	―
RMLI	70 Outperform	5.08B	23.38	―	4.01%	6.10%	-9.48%
TTAM	67 Neutral	1.23B	18.28	―	1.69%	9.07%	38.76%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
DANE	58 Neutral	2.87B	150.52	―	2.98%	5.94%	-52.48%
NVLG	57 Neutral	664.14M	53.50	―	3.05%	22.79%	―